Key Highlights

  • Compass shares are trading down 26.79% at $8.47, against a previous close of $11.57.
  • No company-specific negative catalyst has been identified for the decline.
  • COMP360 FDA filing is planned for completion in the fourth quarter.

Compass Pathways (NASDAQ:CMPS) shares are trading down 26.79% at $8.47, against a previous close of $11.57, on heavy Volume of about 12.09 million shares, ahead of its third-quarter results due before the open on Nov. 3. The company has not announced a negative development, and the move has no clear company-specific catalyst. Its only release on Monday was a joint survey on the burden of treatment-resistant depression.

Compass Pathways develops COMP360, a psilocybin treatment, for treatment-resistant depression. The program has reported two positive Phase 3 trials, and the company has been working toward completing its FDA filing. It has received a Commissioner's National Priority Voucher, which can speed regulatory review, and a decision is possible in early 2027.

A Sharp Move Without a Clear Trigger

The shares are trading well below the prior close, and volume of about 12.09 million shares compares with an average near 2.7 million. The decline places the stock close to the lower end of its 52-week range of $4.88 to $15.87, and trailing Earnings Per Share are negative $3.15.

Biotech and healthcare peers were broadly firm, and the sector fund had risen the prior week, so the drop looks specific to the stock. The cause is not identified in the available material, and a move of this size without news can reflect positioning, a change in expectations before earnings or flows that are not visible from public data.

The Survey Released Today

The company's only same-day release was a joint survey with a patient advocacy organization on the burden of treatment-resistant depression. A survey of this kind describes the patient experience and the need for new options, but it does not contain clinical or regulatory information that would be expected to move the shares.

Treatment-resistant depression is a form of major depressive disorder in which patients do not respond adequately to standard antidepressants, and it is a large unmet need that has drawn interest in newer treatment approaches.

Earnings, Filing and What to Watch

Third-quarter results are due before the open on Nov. 3, with consensus looking for a loss of about $0.33 per share. Investors will focus on the planned completion of the COMP360 FDA filing in the fourth quarter, the status of the priority voucher process, spending and the cash position.

Analyst consensus is positive, with an average target near $23, although one research website downgraded the stock over the weekend. The gap between those targets and the current price shows how much the shares have moved.

The earnings update should show whether management confirms the fourth-quarter filing timing and whether it gives any new detail on regulatory interactions. A clear reaffirmation would address one of the main risks, while any delay would raise concern given how important the filing is to the stock's outlook. Until the company reports, the decline remains unexplained.